M. V. D. Brekel

发表

UvA-DARE Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer

F. Hoebers, B. Slotman, S. Zerp, 2015 .

UvA-DARE (Digital Feasibility of primary tumor culture models and preclinical prediction assays for head and neck cancer: A narrative review

S. Willems, R. Spijker, J. Neefjes, 2015 .

Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer

Jan-Jakob Sonke, Frank Hoebers, Philippe Lambin, 2013, BMC Cancer.

Solving periprosthetic leakage with a novel prosthetic device

F. Hilgers, J. Petersen, M. V. D. Brekel, 2018, The Laryngoscope.

CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer

F. Hoebers, E. Schuuring, C. Rasch, 2010, Clinical Cancer Research.

Detecting and analysing spontaneous oral cancer speech in the wild

Odette Scharenborg, Rob van Son, Bence Mark Halpern, 2020, INTERSPEECH.

Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer

P. Lambin, H. Bartelink, F. Hoebers, 2013, BMC Cancer.

OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent

M. O’Connor, J. Jonkers, M. Verheij, 2015 .

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib

J. Schellens, M. Verheij, J. Schellens, 2019, BMC Cancer.

PV-0312 Distributed learning in radiomics to predict overall survival in head and neck cancer

P. Lambin, F. Hoebers, J. Unkelbach, 2019, Radiotherapy and Oncology.

Nasopharyngeal brush biopsies and detection of nasopharyngeal cancer in a high-risk population.

J. Irish, D. Payne, J. Freeman, 1999, Journal of the National Cancer Institute.